9.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
9.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
9.6 Global Plasma Protease C1-inhibitor Market - Opportunity Analysis Index,
By Type,
By Product Type,
By Dosage Form,
By Administration Route,
and Region, 2024 - 2031
10. North America Global Plasma Protease C1-inhibitor Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
10.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.1.1 Hereditary Angioedema (HAE)
10.1.2 Acquired Angioedema (AAE)
10.2 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.2.1 Plasma-derived C1-inhibitor
10.2.2 Recombinant C1-inhibitor
10.3 By Dosage Form Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.3.1 Injectable Solution
10.3.2 Lyophilized Powder for Reconstitution
10.4 By Administration Route Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.4.1 Intravenous (IV)
10.4.2 Subcutaneous (SC).
10.5 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
10.5.1 United States
10.5.2 Canada
10.6 North America
Global Plasma Protease C1-inhibitor Market – Opportunity Analysis Index,
By Type,
By Product Type,
By Dosage Form,
By Administration Route,
and Country, 2024 - 2031
10.7 Regional Trends Analysis
10.8 North America Global Plasma Protease C1-inhibitor Market Research Report - Company Profiles
10.8.1 Company 1 (United States)
10.8.2 Company 2 (Canada)
10.8.3 Company 3 (Canada)
11. Europe Global Plasma Protease C1-inhibitor Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
11.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.1.1 Hereditary Angioedema (HAE)
11.1.2 Acquired Angioedema (AAE)
11.2 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.2.1 Plasma-derived C1-inhibitor
11.2.2 Recombinant C1-inhibitor
11.3 By Dosage Form Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.3.1 Injectable Solution
11.3.2 Lyophilized Powder for Reconstitution
11.4 By Administration Route Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.4.1 Intravenous (IV)
11.4.2 Subcutaneous (SC).
11.5 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
11.5.1 Germany
11.5.2 United Kingdom
11.5.3 France
11.5.4 Spain
11.5.5 Italy
11.5.6 Russia
11.5.7 Netherlands
11.5.8 Poland
11.5.9 Rest of Europe
11.6 Europe
Global Plasma Protease C1-inhibitor Market – Opportunity Analysis Index,
By Type,
By Product Type,
By Dosage Form,
By Administration Route,
and Country, 2024 - 2031
11.7 Regional Trends Analysis
11.8 Europe Global Plasma Protease C1-inhibitor Market Research Report - Company Profiles
11.8.1 Company 1 (Germany)
11.8.2 Company 2 (United Kingdom)
11.8.3 Company 3 (United Kingdom)
12. Asia-Pacific Global Plasma Protease C1-inhibitor Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
12.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.1.1 Hereditary Angioedema (HAE)
12.1.2 Acquired Angioedema (AAE)
12.2 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.2.1 Plasma-derived C1-inhibitor
12.2.2 Recombinant C1-inhibitor
12.3 By Dosage Form Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.3.1 Injectable Solution
12.3.2 Lyophilized Powder for Reconstitution
12.4 By Administration Route Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.4.1 Intravenous (IV)
12.4.2 Subcutaneous (SC).
12.5 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
12.5.1 China
12.5.2 Japan
12.5.3 India
12.5.4 South Korea
12.5.5 Australia & NZ
12.5.6 ASEAN
12.5.7 Rest of Asia-Pacific
12.6 Asia-Pacific
Global Plasma Protease C1-inhibitor Market – Opportunity Analysis Index,
By Type,
By Product Type,
By Dosage Form,
By Administration Route,
and Country, 2024 - 2031
12.7 Regional Trends Analysis
12.8 Asia-Pacific Global Plasma Protease C1-inhibitor Market Research Report - Company Profiles
12.8.1 Company 1 (China)
12.8.2 Company 2 (Japan)
12.8.3 Company 3 (Japan)
13. Latin America Global Plasma Protease C1-inhibitor Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
13.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.1.1 Hereditary Angioedema (HAE)
13.1.2 Acquired Angioedema (AAE)
13.2 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.2.1 Plasma-derived C1-inhibitor
13.2.2 Recombinant C1-inhibitor
13.3 By Dosage Form Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.3.1 Injectable Solution
13.3.2 Lyophilized Powder for Reconstitution
13.4 By Administration Route Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.4.1 Intravenous (IV)
13.4.2 Subcutaneous (SC).
13.5 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Argentina
13.5.4 Peru
13.5.5 Colombia
13.5.6 Rest of Latin America
13.6 Latin America
Global Plasma Protease C1-inhibitor Market – Opportunity Analysis Index,
By Type,
By Product Type,
By Dosage Form,
By Administration Route,
and Country, 2024 - 2031
13.7 Regional Trends Analysis
13.8 Latin America Global Plasma Protease C1-inhibitor Market Research Report - Company Profiles
13.8.1 Company 1 (Brazil)
13.8.2 Company 2 (Mexico)
13.8.3 Company 3 (Mexico)
14. Middle East & Africa Global Plasma Protease C1-inhibitor Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
14.1 By Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
14.1.1 Hereditary Angioedema (HAE)
14.1.2 Acquired Angioedema (AAE)
14.2 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
14.2.1 Plasma-derived C1-inhibitor
14.2.2 Recombinant C1-inhibitor
14.3 By Dosage Form Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
14.3.1 Injectable Solution
14.3.2 Lyophilized Powder for Reconstitution
14.4 By Administration Route Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
14.4.1 Intravenous (IV)
14.4.2 Subcutaneous (SC).
14.5 Country Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
14.5.1 Saudi Arabia
14.5.2 UAE
14.5.3 South Africa
14.5.4 Egypt
14.5.5 Israel
14.5.6 Rest of Middle East and Africa
14.6 Middle East & Africa
Global Plasma Protease C1-inhibitor Market – Opportunity Analysis Index,
By Type,
By Product Type,
By Dosage Form,
By Administration Route,
and Country, 2024 - 2031
14.7 Regional Trends Analysis
14.8 Middle East & Africa Global Plasma Protease C1-inhibitor Market Research Report - Company Profiles
14.8.1 Company 1 (Saudi Arabia)
14.8.2 Company 2 (UAE)
14.8.3 Company 3 (UAE)
15. Competition Landscape
15.1 Strategic Dashboard of Top Market Players
15.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
15.2.1 Shire (Takeda Pharmaceutical Company)
15.2.2 CSL Behring
15.2.3 Pharming Group NV
15.2.4 Sanquin
16. Data Collection Method and Research Approach 17. Principal Presumptions and Acronyms
Methodology & Credibility
Built for enterprise decisions, not vanity metrics.
Triangulated Sizing
Bottom-up, top-down, and peer benchmarks reconciled by analysts.
Primary + Secondary Research
Executive interviews combined with validated public and paid sources.
Scenario & Sensitivity
Base, bull and bear cases to stress-test strategic moves.
Need Confidence Fast?
We’ll map your questions to the report in 15 minutes.